Ani Pharmaceuticals Inc Sample Contracts

Ani Pharmaceuticals Inc – Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential Portions are marked: [***] AMENDED AND RESTATED CREDIT AGREEMENT among ANI PHARMACEUTICALS, INC., as Borrower, CERTAIN DOMESTIC SUBSIDIARIES OF THE BORROWER FROM TIME TO TIME PARTY HERETO, as Guarantors, THE LENDERS PARTY HERETO, and CITIZENS BANK, N.A., as Administrative Agent Dated as of December 27, 2018 CITIZENS BANK, N.A., as Lead Arranger and Bookrunner THE HUNTINGTON NATI (February 27th, 2019)

THIS AMENDED AND RESTATED CREDIT AGREEMENT, dated as of December 27, 2018, is by and among ANI PHARMACEUTICALS, Inc., a Delaware corporation (the “Borrower”), the Guarantors (as hereinafter defined), the Lenders (as hereinafter defined) and CITIZENS BANK, N.A., a national banking association, as administrative agent for the Lenders hereunder (in such capacity, the “Administrative Agent”).

Ani Pharmaceuticals Inc – A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation December 2018 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about price increases, the Company’s future operations, products, financial position, operating results and prospects, the Company’s pipeline or potential markets (December 27th, 2018)
Ani Pharmaceuticals Inc – STOCK PURCHASE AGREEMENT Dated As Of August 6, 2018 By and Among WellSpring Pharma Services Inc., as the Company, WSP Pharma Holdings, LLC, as Seller, ANI Pharmaceuticals Canada Inc., as Purchaser, and ANI Pharmaceuticals, Inc., as Parent (solely for purposes of Section 8.18) (November 6th, 2018)

This STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of August 6, 2018, is by and among (i) WellSpring Pharma Services Inc., a Nova Scotia company limited by shares (the “Company”), (ii) WSP Pharma Holdings, LLC, a Delaware limited liability company (“Seller”), (iii) ANI Pharmaceuticals Canada Inc., a Nova Scotia company limited by shares (“Purchaser”), and (iv) ANI Pharmaceuticals, Inc., a Delaware corporation (“Parent”) (solely for purposes of Section 8.18).

Ani Pharmaceuticals Inc – Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential Portions are marked: [***] ASSET PURCHASE AGREEMENT by and among ASTRAZENECA AB, ASTRAZENECA UK LIMITED and ANI PHARMACEUTICALS, INC. Dated as of December 29, 2017 Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the Securities Act of 1933, as amended. Confidentia (February 27th, 2018)
Ani Pharmaceuticals Inc – Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential Portions are marked: [***] (February 27th, 2018)

THIS CREDIT AGREEMENT, dated as of December 29, 2017, is by and among ANI PHARMACEUTICALS, Inc., a Delaware corporation (the “Borrower”), the Guarantors (as hereinafter defined), the Lenders (as hereinafter defined) and CITIZENS BANK, N.A., a national banking association, as administrative agent for the Lenders hereunder (in such capacity, the “Administrative Agent”).

Ani Pharmaceuticals Inc – FIRST AMENDMENT TO CREDIT AGREEMENT (February 27th, 2018)

THIS FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of February 5, 2018, is by and among ANI PHARMACEUTICALS, INC., a Delaware corporation (the “Borrower”), the Guarantors party hereto, the Lenders (as hereinafter defined) party hereto, and CITIZENS BANK, N.A., a national banking association, as administrative agent for the Lenders under the Credit Agreement (as hereinafter defined) (in such capacity, the “Administrative Agent”). Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed thereto in the Credit Agreement.

Ani Pharmaceuticals Inc – A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation August 2017 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about price increases, the Company’s future operations, products financial position, operating results and prospects , the Company’s pipeline or potential markets th (August 8th, 2017)
Ani Pharmaceuticals Inc – Contract (June 19th, 2017)

A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Investor Presentation June 20, 2017

Ani Pharmaceuticals Inc – ANI PHARMACEUTICALS, INC. Issuer AND as Trustee INDENTURE Dated as of , 20 Debt Securities CROSS-REFERENCE TABLE(1) (June 12th, 2017)

INDENTURE, dated as of , 20 , among ANI PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and ________________________________, a national banking association organized under the laws of the United States, as trustee (the “Trustee”):

Ani Pharmaceuticals Inc – ASSET PURCHASE AGREEMENT between HOLMDEL PHARMACEUTICALS, LP and ANI PHARMACEUTICALS, INC. DATED AS OF FEBRUARY 23, 2017 (May 4th, 2017)

This Asset Purchase Agreement is made and entered into as of the 23rd day of February 2017, by and between Holmdel Pharmaceuticals, LP, a Delaware limited partnership (“Seller”) and ANI Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (“Purchaser”).

Ani Pharmaceuticals Inc – ASSET PURCHASE AGREEMENT between CRANFORD PHARMACEUTICALS, LLC and ANI PHARMACEUTICALS, INC. DATED AS OF FEBRUARY 23, 2017 (May 4th, 2017)

This Asset Purchase Agreement is made and entered into as of the 23rd day of February 2017, by and between Cranford Pharmaceuticals, LLC, a Delaware limited liability company (“Seller”) and ANI Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (“Purchaser”).

Ani Pharmaceuticals Inc – AMENDED AND RESTATED BYLAWS OF ANI PHARMACEUTICALS, INC. A Delaware Corporation (the “Corporation”) (February 16th, 2017)
Ani Pharmaceuticals Inc – A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation August 2016 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about price increases, the Company’s future operations, products financial position, operating results and prospects , the Company’s pipeline or potential markets th (August 16th, 2016)
Ani Pharmaceuticals Inc – A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation August 2016 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about price increases, the Company’s future operations, products financial position, operating results and prospects , the Company’s pipeline or potential markets th (August 11th, 2016)
Ani Pharmaceuticals Inc – ANI PHARMACEUTICALS, INC., ANIP ACQUISITION COMPANY, as Borrowers and ANIP PARTNER, LLC, AP EUROPEAN HOLDINGS, LLC, ANIP CO-OP, LLC, as Guarantors LOAN AND SECURITY AGREEMENT Dated: May 12, 2016 CITIZENS BUSINESS CAPITAL, A division of Citizens Asset Finance, Inc., Individually and as Administrative Agent and Collateral Agent for any Lender which is or becomes a party hereto (August 4th, 2016)

THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) is made as of this 12th day of May, 2016, by and among CITIZENS BUSINESS CAPITAL, a division of Citizens Asset Finance, Inc., a New York corporation (“Citizens”), individually as a Lender, as administrative agent (in such capacity, “Administrative Agent”) for itself and any other financial institution which is or becomes a party hereto as a lender in accordance with the terms hereof (each such financial institution, including Citizens, is referred to hereinafter individually as a “Lender” and collectively as the “Lenders”), and as collateral agent (in such capacity, “Collateral Agent”) for the Lenders, the Lenders and ANI Pharmaceuticals, Inc., a Delaware corporation (“Parent”), and its Subsidiary, ANIP Acquisition Company, a Delaware (“ANIP”, and together with Parent, jointly and severally, individually a “Borrower” and collectively “Borrowers”), and the following Subsidiaries of the Borrowers, as guarantors: ANIP Partner, LLC, a Del

Ani Pharmaceuticals Inc – ANI Pharmaceuticals Enters Into Exclusive Distribution and Supply Agreement for Hydroxyprogesterone Caproate Injection USP (May 17th, 2016)

BAUDETTE, Minn., May 17, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the signing of an exclusive distribution and supply agreement with Aspen Global Incorporated for Hydroxyprogesterone Caproate Injection ("HPC") USP 250mg/mL in 5mL vials. Aspen will be responsible for supplying the finished goods and ANI Pharmaceuticals will be responsible for marketing and distribution in the U.S. Aspen's product was approved by FDA in August 2015 (ANDA# 200271) and ANI intends to commercialize HPC in the near term. For product inquiries, please contact ANI at 218-634-3601.

Ani Pharmaceuticals Inc – ANI Pharmaceuticals Enters Three Year $30 Million Asset Based Line of Credit with Citizens Bank (May 17th, 2016)

BAUDETTE, Minnesota, May 13, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has entered a new three year senior secured asset-based revolving credit facility for up to $30 million. This facility will be secured by inventory and certain other working capital and related assets of ANI Pharmaceuticals, Inc.

Ani Pharmaceuticals Inc – ASSET PURCHASE AGREEMENT between CRANFORD PHARMACEUTICALS, LLC, and ANI PHARMACEUTICALS, INC. DATED AS OF MARCH 10, 2016 (May 5th, 2016)

This Asset Purchase Agreement is made and entered into as of the 10th day of March 2016, by and between Cranford Pharmaceuticals, LLC, a Delaware limited liability company (“Seller”) and ANI Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (“Purchaser”).

Ani Pharmaceuticals Inc – ASSET PURCHASE AGREEMENT between H2-PHARMA, llc AND ANI PHARMACEUTICALS, INC. DATED AS OF JANUARY 28, 2016 (May 5th, 2016)

This Asset Purchase Agreement is made and entered into as of the 28th day of January 2016, by and between H2-Pharma, LLC, a Florida limited liability company (“Seller”) and ANI Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (“Purchaser”).

Ani Pharmaceuticals Inc – Re: Employment Offer (April 27th, 2016)

On behalf of ANIP Acquisition Company (d/b/a ANI Pharmaceuticals) (the “Company”), I am delighted to offer you employment as Vice President & Chief Financial Officer, reporting directly to ANI’s President and Chief Executive Officer. The purpose of this letter is to set forth the terms of this offer.

Ani Pharmaceuticals Inc – SEPARATION AGREEMENT AND RELEASE (April 27th, 2016)

SEPARATION AGREEMENT AND RELEASE (this "Agreement"), dated as of April 26, 2016, by and between ANI Pharmaceuticals, Inc., a Delaware corporation (the "Company") and Charlotte Arnold ("Executive"). The Company and the Executive are sometimes individually referred to herein as a "Party" or collectively as the "Parties."

Ani Pharmaceuticals Inc – A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation January 2016 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about price increases, the Company’s future operations, products financial position, operating results and prospects , the Company’s pipeline or potential markets t (January 11th, 2016)
Ani Pharmaceuticals Inc – Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential Portions are marked: [***] AMENDMENT NO. 2 TO ASSET PURCHASE AGREEMENT (November 3rd, 2015)

This Amendment No. 2 to Asset Purchase Agreement is dated as of July 10, 2015 (the "Amendment") and is by and between Teva Pharmaceuticals USA, Inc., a Delaware corporation and those of its affiliates that own the Amendment No. 2 ANDAs (as defined below) (collectively, "Teva"), on the one hand, and ANI Pharmaceuticals, Inc., a Delaware corporation ("Buyer") on the other hand.

Ani Pharmaceuticals Inc – Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential Portions are marked: [***] ASSET PURCHASE AGREEMENT By and between Merck Sharp & Dohme B.V. and ANI PHARMACEUTICALS, INC. Dated as of September 18, 2015 Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential Portions (November 3rd, 2015)

This Asset Purchase Agreement (this “Agreement”) is made and executed as of September 18, 2015 (the “Effective Date”), by and between Merck Sharp & Dohme B.V., a limited liability company (a Besloten Vennootschap) organized and existing under the Laws of the Netherlands (“Seller”), and ANI Pharmaceuticals, Inc., a Delaware corporation (“Buyer”). Seller and Buyer are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

Ani Pharmaceuticals Inc – Contract (September 21st, 2015)

A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Acquisition of Corticotropin and Corticotropin - Zinc NDAs September 2015

Ani Pharmaceuticals Inc – A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation May 2015 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about price increases, the Company’s future operations, products financial position, operating results and prospects , the Company’s pipeline or potential markets there (May 15th, 2015)
Ani Pharmaceuticals Inc – ANI Pharmaceuticals Announces Closing of 3.00% Convertible Senior Notes and Full Exercise of Over-Allotment Option (December 10th, 2014)

BAUDETTE, Minnesota (December 10, 2014) - ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (the "Company") today announced that it has closed an underwritten public offering of its 3.00% Convertible Senior Notes due 2019 (the "Notes") in the aggregate principal amount of $143.75 million, which includes the full exercise of the underwriters' over-allotment option to purchase $18.75 million of Notes.

Ani Pharmaceuticals Inc – Nomura Global Financial Products Inc. c/o Nomura Securities International, Inc. Worldwide Plaza 309 West 49th Street 5th Floor New York, NY 10019 December 5, 2014 (December 10th, 2014)

The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the Warrants issued by ANI Pharmaceuticals, Inc. (“Company”) to Nomura Global Financial Products Inc. (“Nomura”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements and serve as the final documentation for the Transaction.

Ani Pharmaceuticals Inc – ANI PHARMACEUTICALS, INC. AND THE BANK OF NEW YORK MELLON, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of December 10, 2014 3.00% Convertible Senior Notes due 2019 (December 10th, 2014)

FIRST SUPPLEMENTAL INDENTURE (this “First Supplemental Indenture”) dated as of December 10, 2014 between ANI PHARMACEUTICALS, INC., a Delaware corporation, as issuer (the “Company”) and THE BANK OF NEW YORK MELLON, a New York banking corporation, as trustee (the “Trustee”).

Ani Pharmaceuticals Inc – INDENTURE ANI PHARMACEUTICALS, INC. and THE BANK OF NEW YORK MELLON as Trustee INDENTURE Dated as of December 10, 2014 Senior Debt Securities (December 10th, 2014)

INDENTURE, dated as of December 10, 2014 between ANI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and The Bank of New York Mellon, a New York banking corporation (the “Trustee”).

Ani Pharmaceuticals Inc – Nomura Global Financial Products Inc. c/o Nomura Securities International, Inc. Worldwide Plaza 309 West 49th Street 5th Floor New York, NY 10019 December 5, 2014 (December 10th, 2014)

The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between Nomura Global Financial Products Inc. (“Nomura”) and ANI Pharmaceuticals, Inc. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements and serve as the final documentation for the Transaction.

Ani Pharmaceuticals Inc – T +1 212 768 6700 (December 8th, 2014)
Ani Pharmaceuticals Inc – Nomura Global Financial Products Inc. c/o Nomura Securities International, Inc. Worldwide Plaza 309 West 49th Street 5th Floor New York, NY 10019 (December 8th, 2014)

The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the Warrants issued by ANI Pharmaceuticals, Inc. (“Company”) to Nomura Global Financial Products Inc. (“Nomura”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements and serve as the final documentation for the Transaction.

Ani Pharmaceuticals Inc – 3.00% Convertible Senior Notes due 2019 ANI PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT (December 8th, 2014)
Ani Pharmaceuticals Inc – ANI Pharmaceuticals Announces Pricing of Upsized $125 Million Convertible Notes Offering (December 8th, 2014)

BAUDETTE, Minn., December 5, 2014 — ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (the "Company") today announced the pricing of an underwritten public offering of $125,000,000 aggregate principal amount of its 3.00% Convertible Senior Notes due 2019 (the "Notes"). The aggregate principal offering amount was increased from the previously announced offering size of $100,000,000. The underwriters have a 30-day option to purchase up to an additional $18,750,000 aggregate principal amount of the Notes from the Company, solely to cover over-allotments, if any. The initial conversion rate of the Notes will be 14.3916 shares of the Company's common stock per $1,000 principal amount of Notes, which is equal to a conversion price of approximately $69.48 per share, subject to adjustment in certain circumstances. As a result of the convertible note hedge and warrant transactions described below, the initial effective conversion price for the Notes, solely from the perspective of the Company, is $96.2